Lupin receives approval for Colesevelam Hydrochloride Tablets

Pharma major Lupin Limited (Lupin) announced today that it has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Welchol® Tablets, 625 mg, of Daiichi Sankyo, Inc.

Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to:

- reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.

- reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Colesevelam Hydrochloride Tablets (RLD: Welchol®) had an annual sales of approximately USD 159 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.972 as compared to the previous close of Rs. 970.4. The total number of shares traded during the day was 81738 in over 2447 trades.

The stock hit an intraday high of Rs. 977 and intraday low of 955.9. The net turnover during the day was Rs. 79304529.

Source : Equity Bulls

Keywords